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 INTRODUCTION 
Under the auspices of the U.S. Department of Energy (USDOE), researchers 
from the Lawrence Livermore National Laboratory (LLNL) have recently implemented a 
series of initiatives to address long-term radiological surveillance needs at former 
nuclear test sites in the Republic of the Marshall Islands (RMI). The aim of this 
radiological surveillance monitoring program (RSMP) is to provide timely radiation 
protection for individuals in the Marshall Islands with respect to two of the most 
important internally deposited fallout radionuclides—cesium-137 (137Cs) and long-lived 
isotopes 239 and 240 of plutonium (239+240Pu)
À
 (Robison et al., 1997 and references 
therein). Therefore, whole-body counting for 137Cs and a sensitive bioassay for the 
presence of 239+240Pu excreted in urine were adopted as the two most applicable in vivo 
analytical methods to assess radiation doses for individuals in the RMI from internally 
deposited fallout radionuclides (see Hamilton et al., 2006a–c; Bell et al., 2002). Through 
2005, the USDOE has established three permanent whole-body counting facilities in the 
Marshall Islands: the Enewetak Radiological Laboratory on Enewetak Atoll, the Utrōk 
Whole-Body Counting Facility on Majuro Atoll, and the Rongelap Whole-Body Counting 
Facility on Rongelap Atoll.  
These whole-body counting facilities are operated and maintained by trained 
Marshallese technicians. Scientists from LLNL provide the technical support and 
training necessary for maintaining quality assurance for data acquisition and dose 
reporting. This technical basis document summarizes the methodologies used to 
calculate the annual total effective dose equivalent (TEDE; or dose for the calendar year 
of measurement) based on whole-body counting of internally deposited 137Cs and the 
measurement of 239+240Pu excreted in urine.  
Whole-body counting provides a direct measure of the total amount (or burden) 
of 137Cs present in the human body at the time of measurement. The amount of 137Cs 
detected is often reported in activity units of kilo-Becquerel (kBq), where 1 kBq equals 
1000 Bq and 1 Bq = 1 nuclear transformation per second (t s–1). [However, in the United 
States the curie (Ci) continues to be used as the unit of radioactivity; where 1 Ci = 
3.7 × 1010 Bq.] The detection of 239Pu and 240Pu in bioassay (urine) samples indicates 
the presence of internally deposited (systemic) plutonium in the body. Urine samples 
that are collected in the Marshall Islands from volunteers participating in the RSMP are 
transported to LLNL, where measurements for 239+240Pu are performed using a state-of-
the-art technology based on Accelerator Mass Spectrometry (AMS) (Hamilton et al., 
2004, 2007; Brown et al., 2004).  
                                                 
À The isotopic composition of plutonium in the terrestrial environment varies depending on the source. For 
example, high-yield atmospheric nuclear tests conducted in the Marshall Islands produced atom ratios of 240Pu to 
239Pu in fallout of about 0.30 to 0.35 (whereas unfissioned, weapons-grade nuclear fuel contains a 240Pu to 239Pu 
atom ratio of approximately 0.05). 
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 The urinary excretion of plutonium by RSMP volunteers is usually described in 
activity units, expressed as micro-Becquerel (μBq) of 239+240Pu (i.e., representing the 
sum of the 239Pu and 240Pu activity) excreted (lost) per day (d–1), where 1 μBq d–1 = 
10–6 Bq d–1 and 1 Bq = 1 t s–1. The systemic burden of plutonium is then estimated from 
biokinetic relationships as described by the International Commission on Radiological 
Protection (e.g., see ICRP, 1990).  
In general, nuclear transformations are accompanied by the emission of energy 
and/or particles in the form of gamma rays (γ), beta particles (β), and/or alpha particles 
(α). Tissues in the human body may adsorb these emissions, where there is a potential 
for any deposited energy to cause biological damage. The general term used to quantify 
the extent of any radiation exposure is referred to as the dose. The equivalent dose is 
defined by the average absorbed dose in an organ or tissue weighted by the average 
quality factor for the type and energy of the emission causing the dose. The effective 
dose equivalent (EDE; as applied to the whole body), is the sum of the average dose 
equivalent for each tissue weighted by each applicable tissue-specific weighing factor 
(which equates to the sensitivity of that tissue to damage by the equivalent radiation 
dose it receives). The SIg unit of effective dose equivalent is the joule per kilogram (J 
kg–1), named the Sievert (Sv). The unit often used by federal and state agencies in the 
United States to describe EDE continues to be the more historical radiation equivalent 
man (rem); where 1 rem = 0.01 Sv.  
Based on the measurements of the internally deposited 137Cs and/or the urinary 
excretion of plutonium, an estimate can be derived for these radionuclides of the annual 
number of nuclear transformations (t y−1) that occurred in the body during the year in 
which measurement was performed. For both radionuclides, this result is the time 
integral of activity in the body of an individual normalized over a one-year measurement 
period, and these radionuclide-specific transformations yield the emissions that are 
responsible for the radionuclide-specific EDE committed for that year.  
In addition to the nuclear transformations that produce the committed EDE for the 
year of measurement of a radionuclide in the body, additional transformations may 
occur in the future due to the presence of residual radioactive material being present in 
the body at the end of the measurement year. Accordingly, the additional EDE 
committed to the individual for the future by such residual material will be a function of 
the biological half-time‡ of the specific radioactive element(s), and the number of 
                                                 
 Systéme International [d'Unités] (International System [of Units]), where the United States has not totally 
implemented the Systéme International d'Unités, especially with respect to units of radioactivity (as discussed 
earlier) and radiation dose. 
g
‡ For the purposes of this discussion, the term biological half-time is to be considered synonymous with the 
term biological half-life or the time in which one half the material is removed from a biological compartment 
(or system) in the absence of additional input to that compartment (or system). 
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 transformations associated with the presence of such residual radioactivity evaluated for 
up to 50 y in the future [which the United States Environmental Protection Agency 
(USEPA) defines for members of the public as a conservative maximum period] in order 
to estimate the expected EDE commitment.  
It is considered appropriate and conforming with the national and international 
recommendations of the USEPA and the ICRP to assign to the year of its measurement 
the EDE commitment that is estimated to occur up to 50 y in the future for a 
radionuclide. Thus, the number of nuclear transformations for a particular radionuclide 
estimated to occur in the body of an individual during the measurement year is summed 
with those estimated to occur for up to 50 y in the future or until the radionuclide 
producing them has been eliminated completely from the body. The corresponding 
radionuclide-specific EDE that is committed from the sum of these transformations 
equals the committed effective dose equivalent (CEDE) for the individual from that 
radionuclide.  
For example, Figures 1a and 1b illustrate the accumulation of absorbed dose and 
the residual burden of 137Cs and 239+240Pu, respectively, as a function of time (in years) 
after a unit uptake. In the case of 137Cs (Fig. 1a), based on its biokinetics for distribution 
and retention (see ICRP, 1990), the integrated total absorbed dose from an initial acute 
uptake occurs about 2 y into the future. In this case, the integrated dose over this 2-y 
period provides a reasonable estimate of the CEDE for the year of measurement. In 
comparison, plutonium has a biological half-life of approximately 20 y to 50 y (see ICRP 
1990) and so its elimination is not likely to occur completely over a typical human 
lifespan.  
The total calendar year dose or TEDE (total effective dose equivalent) for a 
specified age group represents the summation of radionuclide-specific, age-dependent, 
CEDEs for all monitored radionuclides. Under the Marshall Islands RSMP, only the 
CEDE for 137Cs and the CEDE for the 50-y integrated dose from 239+240Pu are summed 
to represent the annual TEDE for the year in which they are measured as these two 
radionuclides represent the two most significant contributors to internal radiation dose 
for exposed members of the public in the Marshall Islands.  
The USEPA has identified 15 mrem y–1 as an annual EDE
ÀÀ
 to “generally be the 
maximum dose limit for humans” (with respect to the combination of external dose and 
CEDE from internally deposited radionuclides for up to 50 years into the future assigned 
to the year of measurement), and applicable as criteria and guidance (but not 
 
 
                                                 
ÀÀ The SI unit used by the international community to represent this effective dose equivalent (EDE) is 0.15 
millisievert (mSv), where 1 mSv = 100 mrem. The annual EDE for internally deposited radionuclides is 
interpreted as the committed effective dose equivalent (CEDE) for up to 50 y into the future assigned to the 
year of measurement. 
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Figure 1 (a and b). Figure 1a illustrates the relationship between absorbed dose from 
137Cs and the corresponding residual burden of 137Cs over time following an initial unit 
uptake; and Figure 1b shows the relationship between absorbed dose from 239+240Pu 
and the residual burden of plutonium with time following an initial unit uptake (after 
ICRP, 1990). 
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 as a dose-based regulation) to control exposures to residual radioactivity above 
background at a hazardous-waste site. This guidance equates to an average excess 
lifetime cancer morbidity (incidence) risk of about 3 × 10–4 (appropriate at the time the 
rationale was explained), based on a 30-y period of exposure (the expected lifetime 
exposure from analysis of population mobility data for the continental U.S.) or a total 
lifetime dose of 450 mrem (i.e., 30 y × 15 mrem y–1) (see ISCORS, 2002; Luftig and 
Weinstock, 1997; and USEPA, 1994). In December 1998, the Nuclear Claims Tribunal 
of the Republic of the Marshall Islands (NCT/RMI) issued a Memorandum of Decision 
and Order that concludes by adopting the USEPA guidance of 15 mrem y–1 EDE as a 
standard that would “… provide the basis on which evidence will be presented to the 
Tribunal for it to determine the need for and cost of radiological rehabilitation of any 
atolls where such action may be warranted” (NTC/RMI, 2004). 
TERMINOLOGY 
It is very important to recognize the subtle distinction in terminology between the 
annual TEDE (or total calendar-year dose) based on whole-body counting for 137Cs and 
bioassay measurements of 239+240Pu excreted in urine, and the CEDE (committed 
effective dose equivalent) that is used specifically in the description of the maximum 
annual dose limit of 15 mrem y–1 (that includes both external and internal dose 
integrated over 50 y). The CEDE calculation assumes that the uptake of 239Pu and 240Pu 
is continuous and chronic, not only for the calendar year of measurement but also for 
50 y into the future. This steady-state assumption implies that the amount of plutonium 
in the body of people will not change over time. Using steady state conditions is 
conservative, that is to say a dose maximizing assumption. Nevertheless, the 
radiological surveillance-monitoring program requires confirmation of elevated levels of 
urinary excretion of plutonium because measured levels may be attributed potentially to 
more acute incremental intake scenarios. In this latter case, a more thorough 
investigation would be conducted to determine the computation of dose more 
accurately. 
Additionally, the CEDE calculation for individuals participating in the RSMP in the 
RMI ignores contributions from external radiation exposure as well as internal doses 
from intakes of fallout radionuclides other than 137Cs and 239Pu and 240Pu, such as 
strontium-90 (90Sr). If such other fallout radionuclides are consumed, the total calendar 
year dose to individuals from exposure to residual fallout contamination in the Marshall 
Islands may be higher than that calculated from only the whole-body counting for 137Cs 
and the bioassay for 239+240Pu in urine.  
The TEDE being assessed for the volunteers participating in the radiological 
surveillance monitoring program in the RMI is computed in units of Sv y–1 and rem y–1, 
and equates to the potential internal biological dose that can occur as a result of 
absorption in tissues and organs of the emissions of radiations produced by the 
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 internally deposited radioactive isotopes 137Cs and 239+240Pu as they undergo nuclear 
transformations during their decay. When only one radionuclide is measured, the TEDE 
for the calendar year and the CEDE for the specific radionuclide for that calendar year 
are identical. When more than one radionuclide is measured, the TEDE is the sum of 
CEDEs corresponding to each of the radionuclides for the calendar year of 
measurement. The annual TEDE based on whole-body counting of 137Cs and the 
bioassay for 239+240Pu in urine is to be compared to the USEPA recommended 
15 mrem y–1 EDE guidance that was adopted by the NCT for the RMI for cleanup and 
rehabilitation of sites contaminated by radioactive fallout. Furthermore, because of the 
long biological half-time of plutonium in the body, any measurement of 239+240Pu in urine 
that is elevated and yields a dose approaching the 15 mrem y−1 may be attributed to a 
recent acute-incremental intake scenario, and in such cases a more thorough 
investigation would be conducted to determine the possible origin of such dose and 
compute it with higher fidelity. 
ASSUMPTIONS 
The mathematical procedures employed to convert whole-body counts of 137Cs 
and in-vitro bioassay measurements of plutonium isotopes in 24-h urine samples to a 
CEDE are based on the following assumptions. First, uptake of these radionuclides is 
considered to be continuous and chronic throughout the year of measurement and, after 
uptake, these radionuclides are distributed across physiological compartments of the 
human body according to model assumptions described by the ICRP (1980; 1990). 
Additionally, the dominant exposure pathways for 137Cs and plutonium isotopes are 
assumed to be ingestion and inhalation, respectively. Furthermore, 240Pu will always be 
found in much smaller quantities than 239Pu and so doses from 239+240Pu are based on 
absolute measurements of 239Pu and 240Pu, even if the only valid measurement of 
excreted plutonium was for 239Pu alone. Finally, the general approach for assessing 
dose from exposure measurements is considered consistent with methods described by 
the ICRP for members of the public in its publications numbers 30 and its supplement to 
Part 1; 56; 67; 69; 71; and 72 (ICRP, 1979 and 1980; 1990; 1994; 1995; 1996a,b). 
METHODS FOR CALCULATING DOSE 
For volunteers participating in this radiological surveillance monitoring program, 
both the whole-body counting of 137Cs and the bioassay measurements of plutonium in 
urine are used to estimate the total activity (Bq) of these radionuclides in the body at the 
time of measurement. The respective measurement(s) of activity for either 137Cs or for 
239+240Pu are then integrated over the entire calendar year to yield an estimate of the 
total number of nuclear transformations for that year (t y–1). 137Cs is considered to be 
distributed in the human body into fractions of 0.1 and 0.9 to each of two compartments, 
with each fraction having a retention half life of 2 and 110 days, respectively (see ICRP, 
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 1980). For 137Cs, the transformations in a one year period are combined with an 
estimate of the number of transformations that occur from the end of the measurement 
period until 50 years into the future (in seconds) by which time this remaining 137Cs 
activity will be eliminated completely from the body (see Fig. 1a), assuming the long 
term biological half-time for 137Cs is 110 days. This sum of nuclear transformations can 
then be multiplied by the respective age-dependent, whole-body committed effective 
dose equivalent (CEDE) conversion factor (e.g., Sv t−1) to obtain the CEDE (for 137Cs) 
during the year of measurement for the individual.  
A similar, but not identical, procedure is used to generate a CEDE for 239+240Pu 
for the different age group categories. Again, this CEDE will represent dose 
commitment for the year in which the exposure measurement is made and for 50 y into 
the future assigned to that year of measurement. In this procedure measurement(s) of 
daily excretion rate(s) integrated over the entire calendar year estimate the total 
239+240Pu activity (μBq) excreted for that calendar year for an individual.  This value is 
then multiplied by a factor that converts this annual excreted 239+240Pu activity to a 
whole-body 50-y CEDE (assigned to the year of measurement).  
The “conversion factor” used to obtain the whole-body 50-y CEDE for 239+240Pu is 
the sum of the conversion factors used to represent each of the organ-specific 50-y 
CEDEs per activity unit excreted in urine annually (i.e., ΣCFCEDE). Each organ-specific 
conversion factor is the 50-y CEDE in that organ per activity unit excreted in urine 
annually (e.g., Sv [for 50 y] μBq−1 [excreted annually]) and is obtained from the 
biokinetic modeling of 239+240Pu activity (Bq) in the organ of interest per activity unit 
excreted in urine daily (μBq d−1). This biokinetic modeling is performed using the IMBA 
Expert™ USDOE-Edition (Phase II) software obtained from ACJ & Associates, Inc. 
(2004). The software is a collection of “Integrated Modules for Bioassay Analysis” 
(IMBA) and features use of the biokinetic model for the actinide elements (thorium, 
neptunium, plutonium, americium, and curium), adopted in ICRP Publication 67 (ICRP, 
1994), along with the values for the transfer rates between its compartments currently 
recommended in ICRP Publication 78 (ICRP, 1998). Figure 2 [adapted from Fig. 9 (p. 
17) in ICRP Publication 78 (ICRP, 1998)] shows the biokinetic model for plutonium.  
The bioassay calculation from IMBA yielding the organ-specific activity of 
239+240Pu per activity unit excreted in urine daily is based on chronic intake (via 
inhalation) of insoluble plutonium under equilibrium conditions. Accordingly, a 
urine-bioassay measurement rate for 239+240Pu activity equal to 1 μBq d−1 is set in IMBA. 
This daily excretion rate of 239+240Pu activity is then used by IMBA to infer a 
corresponding inhalation intake rate of 5.4 μBq d−1 per 1 μBq d−1 excreted of 239+240Pu 
activity. 
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Figure 2.  Biokinetic model for plutonium adapted from Fig. 9 (p. 17) in ICRP 78 (1998); 
adopted in ICRP 67 (1994). 
The IMBA derived intake-rate value then serves as the basis for IMBA to also 
predict corresponding activities of 239+240Pu in the biological compartments (organs) of 
greatest interest [i.e., lungs, liver, cortical (bone) surface, trabecular (bone) surface, 
upper large intestine, and lower large intestine]. Additionally, each organ-specific CFCEDE 
for 239+240Pu (i.e., Bq in organ/[ μBq d−1 excreted in urine]) for a particular age group is 
computed as the product of the following terms: IMBA generated equilibrium activity of 
239+240Pu in an organ of interest (Bq) per 239+240Pu activity unit excreted in urine daily (1 
μBq d−1); a factor for converting day to seconds (8.64 × 104 s d−1); the duration of 
committed dose (50 y); the specific effective energy (SEE) as the energy absorbed per 
unit mass of organ tissue per transformation for the alpha particles in each relevant 
adult organ [MeV/(g × t)]; factors for converting SEE to Sv t–1 [1.6 × 10–13 J MeV−1 × 1 × 
103 g kg−1 × 1 Sv/(J kg−1) = 1.6 × 10–10 (Sv × g) MeV–1]; organ-specific tissue weighting 
factor (dimensionless), representing relative susceptibility of the organ to stochastic 
effects; and adult age-group to the age-group of interest organ-mass ratio 
(dimensionless). 
Because alpha particles dominate the energy deposition (and dose) per unit 
organ mass and have short range, it is assumed that all energy deposition from 
239+240Pu transformations will be in the organ mass of interest only. Accordingly, the 
adult age-group to age-group of interest organ mass is used as a simple correction 
factor to adjust the SEE value in an organ of an adult to one that is appropriate for a 
younger age group of interest. This ratio will always be greater than one because for all 
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 organs, adult organ mass is greater than that for the same organ in younger age 
groups.  
The data used to derive age-dependent, whole-body committed effective dose 
equivalents (CEDE) for the year of intake are tabulated in Appendix A. Specific 
illustrative examples of the application of the equations appears in Appendix B. 
Appendix C provides an earlier (1998-2004) and less precise applied method for 
evaluating the dose from 239+240Pu based on urinary excretion measurements. 
Equations for Determining an Age-Dependent, CEDE for 137Cs from Reported 
Measurement Value(s) for a Calendar Year 
For 137Cs, the number of transformations per year in the body (At; t y–1) predicted 
to occur during the year of measurement are determined using Equation 1: 
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mi = i th measurement of whole-body activity (kBq) in a series from 1 up to N 
measurements taken during the calendar year (e.g., i = 1, 2, … N), and where 
N–1 is equal to zero, the summation term defaults to a value of zero; 
ti = calendar day of i th measurement (e.g., 1, 2, 150, up to 365; or 366 in a leap year; 
and 
ucf = unit conversion factor of 8.64 × 107 [representing the product of 1000 t s–1 
(or Bq)/kBq–1 and 24 h d–1 × 3600 s h–1]. 
The additional committed transformations in the body from 137Cs assigned to the 
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9.01.0  , where Eq. 2 
mN = Nth measurement of whole-body activity (kBq) in a series of up to N 
measurements taken during the calendar year (of measurement; and 
ucf = unit conversion factor of 8.64 × 107 [representing the product of 1000 t/s (or 
Bq)/kBq and 24 h/d × 3600 s/h]. 
Because 137Cs is rapidly removed from the body and will be eliminated well 
before the 50-y duration of the integral (see Fig. 1a), Eq. 2 can be approximated by the 
analytical expression appearing in Eq. 3, 
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 ( ) ( ) 71064.81102ln
9.02
2ln
1.0 ××⎥⎦
⎤⎢⎣
⎡ ×+×=    ddNc mA  , where Eq. 3 
the values of 0.1 and 0.9 (in both Eqs. 2 and 3) represent the fractions of cesium that 
are considered to be distributed into the two biokinetic compartments described by 
ICRP Figs 1a-1b (ICRP, 1980) that possess 2-d and 110-d retention half lives, 
respectively. 
The total number of transformations attributed to the year of measurement (At) is 
then summed with the transformations (Ac) committed into the future that are estimated 
from the last measurement (mN) and assigned to the year of measurement. This 
summation of total activity (AT) is described by Eq. 4: 
Cs to applicable , 137ctT AAA += . Eq. 4 
An age-dependent, CEDE for 137Cs, expressed in units of Sv y–1 or rem y–1 
(where 1 Sv y–1 = 102 rem y–1) is then obtained using Eq. 5 as the product of the value 
of AT and the appropriate age-specific, whole-body dose conversion factor (DCF) as 
found in Table 1. 
Table 1.  Dose conversion factors (DCFs) applicable to 137Cs and expressed as the 
age-dependent, whole-body effective dose equivalent (EDE) per unit nuclear 
ransformation (t).a  t 
Age-dependent, whole-body effective dose 
equivalent (EDE) per unit nuclear transformation 
 
 
 
Applicable age Sv t–1
b
rem t–1
b
Adult male 1.16 × 10–15 1.16 × 10–13
Adult female 1.39 × 10–15 1.39 × 10–13
Teenager (12 to 18 y) 1.41 × 10–15 1.41 × 10–13
Adolescent (7 to 12 y) 2.24 × 10–15 2.24 × 10–13
Child (≤ 7 y) 3.58 × 10–15 3.58 × 10–13
a These DCFs include the products of age-dependent, specific effective energies (SEEs) computed using 
SEECAL software (Cristy and Eckerman, 1995) for 137Cs in specific target organs, and corresponding 
organ-specific tissue weighting factors (wt) obtained from ICRP 56 (1990). See Tables A-1 to A-5 in 
Appendix A for the data used to derive these DCFs for 137Cs. 
b 1 Sv t–1 = 102 rem t–1 or 105 mrem t–1; because 1 rem t–1 = 103 mrem t–1. 
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 group age
137
group age DCF Cs) (for CEDE ×= TA ; where Eq. 5 
 DCFage group = effective dose equivalent (EDE) per unit transformation (i.e., Sv t–1 
or rem t–1) found in Table 1.  
The data supporting the derivation of the age-specific, whole-body EDEs per unit 
transformation appearing in Table 1 are tabulated in Tables A-1 through A-5 of 
Appendix A. Illustrative examples of the application of Equations 1 through 5 to 
hypothetical measurement data are presented in Appendix B. 
Equations for Determining an Age-Dependent CEDE for 239+240Pu from Reported 
Measurement Value(s) for a Calendar Year. 
Confirmed measurements of 239Pu and 240Pu by AMS in 24-h urine voids (in units 
of μBq d–1 = 1 × 10–6 Bq d–1) are identified as the total activity excreted per day (μBq d–
1) for 239+240Pu. The abundance (and therefore activity) of 240Pu is expected to be lower 
than that for 239Pu and make a lesser contribution to the total 239+240Pu activity detected. 
Accordingly, the age dependent CEDE derived from measurements of total 239+240Pu will 
be dominated by the presence of the more abundant 239Pu but includes the contribution 
to dose from the activities of any valid measurements of 240Pu. Under circumstances 
where only the AMS measurement for 239Pu in a 24-h urine void is considered valid and 
positive for a particular sample (i.e., 240Pu is not detected), the total daily excretion rate 
for 239Pu (μBq d–1) is considered to represent the total amount of plutonium activity 
excreted per day (i.e., μBq d–1 for 239+240Pu). In this case, only 239Pu activity would 
actually contribute to the derived age dependent CEDE for 239+240Pu. 
For 239+240Pu, the first step in determining the CEDE is to sum the daily excretion 
rate measurement (Bq d–1) for 239Pu with that for 240Pu obtained by AMS  analysis of  
24-h urine void samples. Then an integrated excretion of 239+240Pu activity (e.g., in μBq) 
for the calendar year (At) is estimated based on the number of 24-h urine samples 
bioassays measured in that calendar year. This calculation is performed using Eq. 1 
with measurements of μBq d–1 as input, where At in this case is applicable to 239+240Pu 
activity excreted for the entire calendar year and is in units of  
μBq y–1. 
For example, 
At = miti + mN 365− tN( )+ mi + mi+1( )2 ti+1 − ti(i =1
N −1∑ )⎡ ⎣ ⎢ 
⎤ 
⎦ ⎥  , where    Eq. 1a 
mi = i th measurement of 239+240Pu activity (µBq d–1) in a series from 1 up to N 
measurements taken during the calendar year (e.g., i = 1, 2, … N), and 
where N – 1 is equal to zero the summation term defaults to a value of zero. 
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   ti = calendar day of i th measurement (e.g., 1, 2, … 150, …  up to 365 d–1; or 
366 d–1 in a leap year). 
An age-dependent, CEDE for 239+240Pu, expressed in units of Sv or mrem and 
assigned to the year of measurement, is calculated in this case as the product of two 
terms (see Eq. 6): 1) the integrated annual activity excreted At (μBq of 239+240Pu y–1); 
and 2) the applicable age-specific (50-y) committed effective dose equivalent 
conversion factor, which is expressed as the CFCEDE (Sv or rem) per 239+240Pu activity 
excretion integrated over the year of measurement (μBq y–1; see Table 2). 
group)  CEDE(age
249+239
group age CF Pu) (for CEDE ×= TA  Eq. 6 
The data supporting the derivation of the age-specific, whole-body effective dose 
equivalents per unit of 239+240Pu excreted over the year of measurement (μBq y–1) 
appearing in Table 2 are determined using data tabulated in Tables A-6 through A-10 of 
Appendix A. Illustrative examples of the application of these algorithms to hypothetical 
measurement data are presented in Appendix B.  
Procedures for Estimating Age-Dependent, Calendar Year Total Effective Dose 
Equivalent (TEDE) From Radionuclide-Specific, Age-Dependent, CEDE(s) 
When only 137Cs or only 239+240Pu measurements are reported for an individual of a 
particular age group in a calendar year, then the total effective dose equivalent (TEDE) 
assigned due to intakes incurred by an individual during the calendar year corresponds 
to the CEDE for the measured radionuclide. When both 137Cs whole-body counting and 
AMS measurement(s) of daily 239+240Pu excretion rate are reported for an individual in a 
calendar year, then the total effective dose equivalent (TEDE) assigned to the year of 
measurement that is due to intakes incurred by an individual during the calendar year in 
which the measurement was made corresponds to the sum of both radionuclide-specific 
CEDEs as shown in Eq. 7. 
Pufor  CEDE  Csfor  CEDE TEDE 240239group age
137
group agegroup age
++=  Eq. 7 
The TEDE is reported in units of mrem y–1 (and is converted by the following 
relationships, 1 Sv = 102 rem = 105 mrem) for comparison to the 15 mrem y–1 maximum 
dose limit adopted as a standard for the RMI. 
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Table 2. Age dependent Conversion Factors (CFCEDE) representing the age-dependent, 
whole-body, (50-y) committed effective dose equivalent (CEDE) per total amount of 
239+240Pu activity excreted during the calendar year (μBq y–1).a   
Sex/Age Sv per μBq y−1 b rem per μBq y−1 b
Adult (> 17 y)  3.3 × 10–7  3.3 × 10–5 
Teenager (12 to 17 y)  5.0 × 10–7  5.0 × 10–5 
Adolescent (range: 7 to 12 y)  8.3 × 10–7  8.3 × 10–5 
Child (2 to 7 y)   1.3 × 10–6  1.3 × 10–4 
a Tables A-6 through A-10 in Appendix A contain the data used to derive the CFCEDE. 
b 1 Sv = 100 rem. 
 
INTERPRETING RESULTS FROM COMPARISON OF CALENDAR YEAR  
TEDEage group TO 15-mrem y−1 TEDE ADOPTED BY 1998 NUCLEAR CLAIMS 
TRIBUNAL DECISION 
The calculations used to derive the total dose from internally deposited 137Cs and 
239+240Pu constitute a mathematical approach that distills complicated numerical 
modeling of intricate biokinetic processes into more easily understood, but 
representative and analytically executable algorithms. For this reason, these algorithms 
are designed to incorporate conservative simplifying default assumptions so that results 
constitute overestimates for the calculated doses for comparison to the 15-mrem y–1 
maximum dose limit adopted as a standard for the RMI. 
This also means that an excess actual lifetime cancer risk will be lower than that 
predicted from the overestimate of total dose. Nevertheless, any calendar year dose 
calculated using the mathematical algorithms and simplifying default assumptions 
described here that either approaches or is equal to or greater than the 15-mrem  y–1 
TEDE maximum dose limit, adopted as a standard for the RMI, will receive further and 
more careful dosimetric re-examination. This reevaluation will either assure that the 
15 mrem annual limit is achieved or help explain why it may be exceeded. In fact, any 
estimate of a TEDE for an individual that is calculated from measurement data to yield a 
value ≥ 10 mrem y–1 (0.1 mSv y–1, where 1 mSv = 100 mrem) will evoke a more 
complete and accurate dose evaluation, and/or investigation of intake. For example, 
these actions will initially involve followup measurements and, depending on the results, 
a dietary evaluation and/or workplace- and residence-history review.  
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Appendix A 
 
 
 
 
Derivation of Age-Dependent, Whole-Body Effective 
Dose Equivalent (EDE) Conversion Factors for 137Cs and 
239+240Pu 
 
 
The derivation of the effective dose equivalent (EDE) conversion factors for 137Cs and 
committed effective dose equivalent (CEDE) conversion factors for 239+240Pu are presented 
in this appendix. Tables A-1 through A-5 show the information used for deriving 137Cs age-
specific, whole-body EDE conversion factors. Tables A-6 through A-10 contains information 
needed for deriving 239+240Pu age-specific, whole-body CEDE conversion factors. 
Additionally, the contribution to age-specific whole-body CEDE from 239+240Pu deposited in 
the upper and lower large intestines is described and found to be insignificant (see Table A-
7 to A-10) 
 
A- 1
 Table A-1. Derivation of 137Cs whole-body effective dose equivalent (EDE) conversion 
factors applicable to adult male. 
 
 
 
Target organ 
 
Tissue 
weighting 
factora 
Specific 
effective energy 
from 137Cs 
(SEE = Sv t–1)b
Specific 
effective energy 
from 137mBa 
(SEE = Sv t–1)b
Organ-specific
EDE conversion
factor  
(Sv t–1)c
Gonads 0.25  4.69 × 10–16  8.01 × 10–16  3.18 × 10–16 
Breasts 0.15  4.69 × 10–16  5.38 × 10–16  1.51 × 10–16 
Lung tissue 0.12  4.69 × 10–16  6.64 × 10–16  1.36 × 10–16 
Red bone marrow 0.12  4.69 × 10–16  6.37 × 10–16  1.33 × 10–16 
Stomach wall 0.06  4.69 × 10–16  7.08  × 10–16  7.06 × 10–17 
Adrenals 0.06  4.69 × 10–16  7.69 × 10–16  7.43 × 10–17 
Lower large intestine 0.06  4.69 × 10–16  7.59 × 10–16  7.37 × 10–17 
Upper large intestine 0.06  4.69 × 10–16  7.33 × 10–16  7.21 × 10–17 
Small intestine wall 0.06  4.69 × 10–16  7.79 × 10–16  7.49 × 10–17 
Thyroid 0.03  4.69 × 10–16  7.00 × 10–16  3.51 × 10–17 
Bone surface 0.03  2.35 × 10–16  6.08 × 10–16  2.53 × 10–17 
Σ = Whole-body EDE conversion factor (Sv t–1)  1.16 × 10–15
a From ICRP (1990). 
b Computed using SEECAL software (Cristy and Eckerman, 1995). 
c Derived as product of tissue weighting factor and sum of specific effective energies for beta 
emission from 137Cs parent and gamma emission from 137mBa progeny, which are considered to 
be present in secular equilibrium.  
A- 2
 Table A-2. Derivation of 137Cs whole-body effective dose equivalent (EDE) conversion 
factors applicable to adult female. 
 
 
 
Target organ 
 
Tissue 
weighting 
factora
Specific 
effective energy 
from 137Cs 
(SEE = Sv t–1)b
Specific 
effective energy 
from 137mBa 
(SEE = Sv t–1)b
Organ-specific
EDE conversion
factor  
(Sv t–1)c
Ovaries 0.25 5.64 × 10–16 9.32 × 10–16 3.74 × 10–16
Breasts 0.15 5.64 × 10–16 6.42 × 10–16 1.81 × 10–16
Lung tissue 0.12 5.64 × 10–16 8.04 × 10–16 1.64 × 10–16
Red bone marrow 0.12 5.64 × 10–16 7.49 × 10–16 1.58 × 10–16
Uterus 0.06 5.64 × 10–16 9.63 × 10–16 9.16 × 10–17
Adrenals 0.06 5.64 × 10–16 9.07 × 10–16 8.82 × 10–17
Lower large intestine 0.06 5.64 × 10–16 8.30 × 10–16 8.36 × 10–17
Upper large intestine 0.06 5.64 × 10–16 7.82 × 10–16 8.07 × 10–17
Small intestine wall 0.06 5.64 × 10–16 9.14 × 10–16 8.87 × 10–17
Thyroid 0.03 5.64 × 10–16 8.43 × 10–16 4.22 × 10–17
Bone surface 0.03 5.64 × 10–16 7.06 × 10–16 3.81 × 10–17
Σ = Whole-body EDE conversion factor (Sv t–1) 1.39 × 10–15
a From ICRP (1990). 
b Computed using SEECAL software (Cristy and Eckerman, 1995). 
c Derived as product of tissue weighting factor and sum of specific effective energies for beta 
emission from 137Cs parent and gamma emission from 137mBa progeny, which are considered 
to be present in secular equilibrium. 
A- 3
 Table A-3. Derivation of 137Cs whole-body effective dose equivalent (EDE) conversion 
factors applicable to 15(±3)-y old (teenager). 
 
 
 
Target organ 
 
Tissue 
weighting 
factora 
Specific 
effective energy 
from 137Cs 
(SEE = Sv t–1)b
Specific 
effective energy 
from 137mBa 
(SEE = Sv t–1)b
Organ-specific 
EDE conversion
factor 
(Sv t–1)c 
Gonads 0.25 5.78 × 10–16 9.38 × 10–16 3.79 × 10–16 
Breasts 0.15 5.78 × 10–16 6.49 × 10–16 1.84 × 10–16 
Lung tissue 0.12 5.78 × 10–16 8.10 × 10–16 1.67 × 10–16 
Red bone marrow 0.12 5.78 × 10–16 7.49 × 10–16 1.59 × 10–16 
Uterus 0.06 5.78 × 10–16 9.71 × 10–16 9.30 × 10–17 
Adrenals 0.06 5.78 × 10–16 9.11 × 10–16 8.94 × 10–17 
Stomach wall 0.06 5.78 × 10–16 8.21 × 10–16 8.39 × 10–17 
Upper large intestine 0.06 5.78 × 10–16 8.37 × 10–16 8.49 × 10–17 
Small intestine wall 0.06 5.78 × 10–16 9.21 × 10–16 9.00 × 10–17 
Thyroid 0.03 5.78 × 10–16 8.50 × 10–16 4.28 × 10–17 
Bone surface 0.03 5.78 × 10–16 7.33 × 10–16 3.93 × 10–17 
Σ = Whole-body EDE conversion factor (Sv t–1)  1.41 × 10–15
a From ICRP (1990). 
b Computed using SEECAL software (Cristy and Eckerman, 1995). 
c Derived as product of tissue weighting factor and sum of specific effective energies for beta 
emission from 137Cs parent and gamma emission from 137mBa progeny, which are considered to be 
present in secular equilibrium.   
A- 4
 Table A-4. Derivation of 137Cs whole-body effective dose equivalent (EDE) conversion 
factors applicable to 10(±3)-y old (pre-teenager). 
 
 
 
Target organ 
 
Tissue 
weighting 
factora
Specific 
effective energy
from 137Cs 
(SEE = Sv t–1)b
Specific 
effective energy 
from 137mBa 
(SEE = Sv t–1)b
Organ-specific
EDE conversion
factor 
(Sv t–1)c
Gonads 0.25 9.78 × 10–16 1.44 × 10–15 6.05 × 10–16
Breasts 0.15 9.78 × 10–16 9.24 × 10–16 2.85 × 10–16
Lung tissue 0.12 9.78 × 10–16 1.20 × 10–15 2.62 × 10–16
Red bone marrow 0.12 9.78 × 10–16 1.15 × 10–15 2.55 × 10–16
Uterus 0.06 9.78 × 10–16 1.48 × 10–15 1.48 × 10–16
Adrenals 0.06 9.78 × 10–16 1.39 × 10–15 1.42 × 10–16
Stomach wall 0.06 9.78 × 10–16 1.23 × 10–15 1.33 × 10–16
Upper large intestine 0.06 9.78 × 10–16 1.25 × 10–15 1.34 × 10–16
Small intestine wall 0.06 9.78 × 10–16 1.41 × 10–15 1.43 × 10–16
Thyroid 0.03 9.78 × 10–16 1.36 × 10–15 7.01 × 10–17
Bone surface 0.03 9.78 × 10–16 1.12 × 10–15 6.30 × 10–17
Σ = Whole-body EDE conversion factor (Sv t–1)  2.24 × 10–15
a From ICRP (1990). 
b Computed using SEECAL software (Cristy and Eckerman, 1995). 
c Derived as product of tissue weighting factor and sum of specific effective energies for beta emission 
from 137Cs parent and gamma emission from 137mBa progeny, which are considered to be present in 
secular equilibrium 
A- 5
 Table A-5. Derivation of 137Cs whole-body effective dose equivalent (EDE) conversion 
factors applicable to 5(±3)-y old (child). 
 
 
 
Target organ 
 
Tissue 
weighting 
factora
Specific 
effective energy 
from 137Cs 
(SEE = Sv t–1)b
Specific 
effective energy 
from 137mBa 
(SEE = Sv t–1)b
Organ specific 
 EDE conversion
factor 
(Sv t–1)c
Gonads 0.25 1.63 × 10–15 2.20 × 10–15 9.57 × 10–16
Breasts 0.15 1.63 × 10–15 1.45 × 10–15 4.62 × 10–16
Lung tissue 0.12 1.63 × 10–15 1.86 × 10–15 4.18 × 10–16
Red bone marrow 0.12 1.63 × 10–15 1.73 × 10–15 4.03 × 10–16
Uterus 0.06 1.63 × 10–15 2.24 × 10–15 2.32 × 10–16
Adrenals 0.06 1.63 × 10–15 2.13 × 10–15 2.26 × 10–16
Lower large intestine 0.06 1.63 × 10–15 1.98 × 10–15 2.17 × 10–16
Upper large intestine 0.06 1.63 × 10–15 2.00 × 10–15 2.18 × 10–16
Small intestine wall 0.06 1.63 × 10–15 2.17 × 10–15 2.28 × 10–16
Thyroid 0.03 1.63 × 10–15 2.17 × 10–15 1.14 × 10–16
Bone surface 0.03 1.63 × 10–15 1.72 × 10–15 1.00 × 10–16
Σ = Whole-body EDE conversion factor (Sv t–1)                                   3.58 × 10–15
a From ICRP (1990). 
b Computed using SEECAL software (Cristy and Eckerman, 1995). 
c Derived as product of tissue weighting factor and sum of specific effective energies for beta 
emission from 137Cs parent and gamma emission from 137mBa progeny, which are considered to 
be present in secular equilibrium.   
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Table A-6. Age-dependent organ mass (g)a, and ratio of adult to age-group organ 
masses (dimensionless). 
 
 
 
Target 
Organ 
 
 
Organ 
Mass 
(g) 
 
 
Ratio: 
adult to 
adult 
 
15 y (teen) 
organ 
mass 
(g) 
 
 
Ratio: 
adult to
teen 
10 y 
(pre-teen) 
organ 
mass 
(g) 
 
 
Ratio: 
adult to
pre-teen 
 
 
5 y (child) 
organ mass 
(g) 
 
 
Ratio: 
adult to
child 
Lungs 1000 1.00 651 1.54 453 2.21 290 3.45 
Liver 1800 1.00 1400 1.29 887 2.03 584 3.08 
Cort. BSb 120 1.00 120 1.00 68 1.76 37 3.24 
Trab. BSb 120 1.00 120 1.00 68 1.76 37 3.24 
Gonadsc 35 1.00 15.5 2.26 1.89 18.52 1.63 21.47 
ULId Wall 210 1.00 168 1.25 93 2.26 55.2 3.80 
LLIe Wall 160 1.00 127 1.26 70 2.29 41.4 3.89 
a From ICRP (1996a) and used for determining specific effective energy (SEE) for non-adult age groups. 
b Mass of endostial tissue weight is used to establish ratios for cortical bone surface (Cort. BS) and 
trabecular bone surface (Trab. BS). 
c Testes serve as conservative approximation for mass of gonads, regardless of gender. 
d ULI = upper large intestine wall. 
e LLI = lower large intestine wall. 
 
 Table A-7. Derivation of 239+240Pu whole-body committed effective dose equivalent conversion factor (CFCEDE) applicable to  
adult (> 17 y). 
Organ 
 
Equilibrium 
organ content 
(Bq per μBq 
d−1 excreted)a
Equilibrium 
organ content 
(Bq per μBq 
excreted 
in 1 yr)b
SEE 
[MeV/(g 
t)] c
Tissue 
weighting 
factord
Transformation
s in organ over
50 yearse
Units 
conversion 
factor 
(Sv g/Mev)f
Organ mass 
ratio (relative
to adult 
organ)g
CFCEDEh 
(Sv per μBq 
excreted 
in 1 y) 
 
 
CFCEDEh 
(mrem per 
μBq excreted
in 1 y) 
Lungs 3.3 × 10-2 9.1 × 10-5 0.1 0.12 1.43 × 10+05 1.60 × 10-10 1 2.7 × 10-7  
Liver 1.3 × 10-2 3.7 × 10-5 0.058 0.05 5.79 × 10+04 1.60 × 10-10 1 2.7 × 10-8  
Cort.BS 1.3 × 10-2 3.4 × 10-5 0.21 0.01 5.40 × 10+04 1.60 × 10-10 1 1.8 × 10-8  
Trab.BS 4.3 × 10-3 1.2 × 10-5 0.21 0.01 1.85 × 10+04 1.60 × 10-10 1 6.2 × 10-9  
Gonadsi 1.7 × 10-5 4.5 × 10-8 3 0.2 7.16 × 10+01 1.60 × 10-10 1 6.9 × 10-9  
ULI 2.5 × 10-7 6.8 × 10-10 0.0023 0.05 1.08 × 10+00 1.60 × 10-10 1 2.0 × 10-14  
LLI 4.5 × 10-7 1.2 × 10-9 0.0038 0.05 1.93 × 10+00 1.60 × 10-10 1 5.9 × 10-14  
       Σ = 3.3 × 10–7 3.3 × 10–2 
A
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a 1 Bq = 1 transformation per second (t s–1), therefore units for equilibrium organ content can also be expressed as t s−1 per μBq d−1 excreted. 
b Values in units of Bq per μBq d−1 excreted are converted to Bq per μBq y−1 excreted by dividing the value in the first column by 365 d y−1. 
c Specific effective energy (SEE) is the energy (MeV) absorbed per unit mass (g) of organ tissue per transformation (t). 
d Tissue weighting factors are from ICRP Publication 60 (ICRP, 1991) and represent the fraction of the overall health risk for developing cancer from 
uniform, whole-body irradiation, attributed to each specific organ. 
e Equates to product of t/s per μBq d−1 excreted; 8.64 × 104 s d−1; and 50-y period of commitment (t μBq−1 over 50 y). 
f Equates to product 1.6 × 10–13 J Mev−1; 1.0 × 103 g kg−1; and 1 Sv/(J kg−1). 
g See Table A-6 for values. 
h Equates to the product of t s−1 per μBq y−1 excreted; 365 d y−1; 8.64 × 104 s d−1; 50 y; SEE [MeV/(g t)]; and units conversion factor [(Sv g)/MeV].  
i Testes serve as an approximation for mass of gonads, regardless of gender.  
Note:  Cort.BS = Cortical bone surface; Trab.BS = Trabecular bone surface; ULI = upper large intestine; and LLI = lower large intestine.  
 
 Table A-8. Derivation of 239+240Pu whole-body committed effective dose equivalent conversion factor (CFCEDE) applicable 
to teenager (12 to 17 y). 
Organ 
Equilibrium 
organ content 
(Bq per μBq 
d−1 excreted)a
Equilibrium 
organ content 
(Bq per μBq 
excreted 
in 1 yr)b
SEE 
[MeV/(g t)]c
Tissue 
weighting
factord
Transformations 
in organ over
50 yearse
Units 
conversion 
factor 
(Sv g/Mev)f
Organ mass 
ratio (relative 
to adult 
organ)g
CFCEDEh 
(Sv per μBq 
excreted 
in 1 y) 
 
CFCEDEh 
(mrem per 
μBq excreted 
in 1 y) 
Lungs 3.3 × 10-2 9.1 × 10-5 0.1 0.12 1.43 × 105 1.60 × 10-10 1.54 4.2 × 10-7  
Liver 1.3 × 10-2 3.7 × 10-5 0.058 0.05 5.79 × 104 1.60 × 10-10 1.29 3.5 × 10-8  
Cort.BS 1.3 × 10-2 3.4 × 10-5 0.21 0.01 5.40 × 104 1.60 × 10-10 1 1.8 × 10-8  
Trab.BS 4.3 × 10-3 1.2 × 10-5 0.21 0.01 1.85 × 104 1.60 × 10-10 1 6.2 × 10-9  
Gonadsi 1.7 × 10-5 4.5 × 10-8 3 0.2 7.16 × 101 1.60 × 10-10 2.26 1.6 × 10-8 
ULI 2.5 × 10-7 6.8 × 10-10 0.0023 0.05 1.08 × 100 1.60 × 10-10 1.25 2.5 × 10-14 
LLI 4.5 × 10-7 1.2 × 10-9 0.0038 0.05 1.93 × 100 1.60 × 10-10 1.26 7.4 × 10-14  
       Σ = 5.0 × 10–7 5.0 × 10–2 
A
-9
a 1 Bq = 1 transformation per second (t s–1), therefore units for equilibrium organ content can also be expressed as t s−1 per μBq d−1 excreted. 
b Values in units of Bq per μBq d−1 excreted are converted to Bq per μBq y−1 excreted by dividing the value in the first column by 365 d y−1. 
c Specific effective energy (SEE) is the energy (MeV) absorbed per unit mass (g) of organ tissue per transformation (t). 
d Tissue weighting factors are from ICRP Publication 60 (ICRP, 1991) and represent the fraction of the overall health risk for developing cancer 
from uniform, whole-body irradiation, attributed to each specific organ. 
e Equates to product of t s−1 per μBq d−1 excreted;  8.64 × 104 s d−1; and 50-y period of commitment (t μBq−1 over 50 y). 
f Equates to product 1.6 × 10–13 J Mev−1; 1.0 × 103 g kg−1; and 1 Sv/(J kg−1). 
g See Table A-6 for values. 
h Equates to the product of t/s per μBq y−1 excreted; 365 d y−1; 8.64 × 104 s d−1; 50 y; SEE [MeV/(g t)]; and units conversion factor [(Sv g)/MeV].  
i Testes serve as an approximation for mass of gonads, regardless of gender.  
Note:  Cort.BS = Cortical bone surface; Trab.BS = Trabecular bone surface; ULI = upper large intestine; and LLI = lower large intestine.  
 
 Table A-9. Derivation of 239+240Pu whole-body committed effective dose equivalent conversion factor (CFCEDE) 
applicable pre-teenager (7 to 12 y). 
Organ 
Equilibrium 
organ content 
(Bq per μBq 
d−1 excreted)a
Equilibrium 
organ content 
(Bq per μBq 
excreted 
in 1 yr)b
SEE 
[MeV/(g t)]c
Tissue 
weighting 
factord
Transformation
s in organ over
50 yearse
Units 
conversion 
factor 
(Sv g/Mev)f
Organ mass 
ratio (relative 
to adult 
organ)g
CFCEDEh 
(Sv per μBq 
excreted 
in 1 y) 
 
CFCEDEh  
(mrem per 
μBq excreted 
in 1 y) 
Lungs 3.3 × 10-2 9.1 × 10-5 0.1 0.12 1.43 × 105 1.60 × 10-10 2.21 6.1 × 10-7  
Liver 1.3 × 10-2 3.7 × 10-5 0.058 0.05 5.79 × 104 1.60 × 10-10 2.03 5.5 × 10-8  
Cort. BS 1.3 × 10-2 3.4 × 10-5 0.21 0.01 5.40 × 104 1.60 × 10-10 1.76 3.2 × 10-8  
Trab. BS 4.3 × 10-3 1.2 × 10-5 0.21 0.01 1.85 × 104 1.60 × 10-10 1.76 1.1 × 10-8  
Gonadsi 1.7 × 10-5 4.5 × 10-8 3 0.2 7.16 × 101 1.60 × 10-10 18.52 1.3 × 10-7 
ULI 2.5 × 10-7 6.8 × 10-10 0.0023 0.05 1.08 × 100 1.60 × 10-10 2.26 4.5 × 10-14 
LLI 4.5 × 10-7 1.2 × 10-9 0.0038 0.05 1.93 × 100 1.60 × 10-10 2.29 1.3 × 10-13 
 
       Σ = 8.3 × 10–7 8.3 × 10–2 
A
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a 1 Bq = 1 transformation per second (t s–1), therefore units for equilibrium organ content can also be expressed as t s−1 per μBq d−1 excreted. 
b Values in units of Bq per μBq d−1 excreted are converted to Bq per μBq y−1 excreted by dividing the value in the first column by 365 d y−1. 
c Specific effective energy (SEE) is the energy (MeV) absorbed per unit mass (g) of organ tissue per transformation (t). 
d Tissue weighting factors are from ICRP Publication 60 (ICRP, 1991) and represent the fraction of the overall health risk for developing cancer 
from uniform, whole-body irradiation, attributed to each specific organ. 
e Equates to product of t/s per μBq d−1 excreted;  8.64 × 104 s d−1; and 50-y period of commitment (t μBq−1 over 50 y). 
f Equates to product 1.6 × 10–13 J Mev−1; 1.0 × 103 g kg−1; and 1 Sv/(J kg−1). 
g See Table A-6 for values. 
h Equates to the product of t s−1 per μBq y−1 excreted; 365 d y−1; 8.64 × 104 s d−1; 50 y; SEE [MeV/(g t)]; and units conversion factor [(Sv 
g)/MeV].  
i Testes serve as an approximation for mass of gonads, regardless of gender.  
Note:  Cort.BS = Cortical bone surface; Trab.BS = Trabecular bone surface; ULI = upper large intestine; and LLI = lower large intestine.  
 
Table A-10. Derivation of 239+240Pu whole-body committed effective dose equivalent conversion factor (CFCEDE) applicable 
to child (2 to 7 y). 
Organ 
Equilibrium 
organ content 
(Bq per μBq 
d−1 excreted)a
Equilibrium 
organ content 
(Bq per μBq 
excreted 
in 1 yr)b
SEE 
[MeV/(g t)]c
Tissue 
weighting 
factord
Transformations 
in organ over
50 yearse
Units 
conversion 
factor 
(Sv g/Mev)f
Organ mass 
ratio (relative 
to adult 
organ)g
CFCEDEh 
(Sv per μBq 
excreted  
in 1 y) 
 
CFCEDEh 
(mrem per 
μBq excreted 
in 1 y) 
Lungs 3.3 × 10-2 9.1 × 10-5 0.1 0.12 1.43 × 105 1.60 × 10-10 3.45 9.5 × 10-7  
Liver 1.3 × 10-2 3.7 × 10-5 0.058 0.05 5.79 × 104 1.60 × 10-10 3.08 8.3 × 10-8  
Cort. BS 1.3 × 10-2 3.4 × 10-5 0.21 0.01 5.40 × 104 1.60 × 10-10 3.24 5.9 × 10-8  
Trab. BS 4.3 × 10-3 1.2 × 10-5 0.21 0.01 1.85 × 104 1.60 × 10-10 3.24 2.0 × 10-8  
Gonadsi 1.7 × 10-5 4.5 × 10-8 3 0.2 7.16 × 101 1.60 × 10-10 21.47 1.5 × 10-7 
ULI 2.5 × 10-7 6.8 × 10-10 0.0023 0.05 1.08 × 100 1.60 × 10-10 3.8 7.6 × 10-14 
LLI 4.5 × 10-7 1.2 × 10-9 0.0038 0.05 1.93 × 100 1.60 × 10-10 3.89 2.3 × 10-13 
 
       Σ = 1.3 × 10–6 1.3 × 10–1
a 1 Bq = 1 transformation per second (t s–1), therefore units for equilibrium organ content can also be expressed as t s–1 per μBq d–1 excreted. 
b Values in units of Bq per μBq d–1 excreted are converted to Bq per μBq y–1 excreted by dividing the value in the first column by 365 d y–1. 
c Specific effective energy (SEE) is the energy (MeV) absorbed per unit mass (g) of organ tissue per transformation (t). 
d Tissue weighting factors are from ICRP Publication 60 (ICRP, 1991) and represent the fraction of the overall health risk for developing cancer 
from uniform, whole-body irradiation, attributed to each specific organ. 
e Equates to product of t s–1 per μBq d–1 excreted;  8.64 × 104 s d–1; and 50-y period of commitment (t /μBq over 50 y). 
f Equates to product 1.6 × 10–13 J Mev–1; 1.0 × 103 g kg–1; and 1 Sv/(J kg–1). 
g See Table A-6 for values. 
h Equates to the product of t s–1 per μBq y–1 excreted; 365 d y–1; 8.64 × 104 s d–1; 50 y; SEE [MeV/(g t)]; and units conversion factor [(Sv g)/MeV].  
 
 
Note:  Cort.BS = Cortical bone surface; Trab.BS = Trabecular bone surface; ULI = upper large intestine; and LLI = lower large intestine.  
 Testes serve as an approximation for mass of gonads, regardless of gender.  i
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Appendix B 
 
Illustrative Sample Calculations for Hypothetical 
Measurements 
 
        
  
The dosimetric calculations for determining the age-specific, annual TEDEage group 
from activity measurement(s) of 137Cs (whole-body) and 239+240Pu (in urine) that have 
been applied since 2005 for the Marshall Islands radiological surveillance monitoring 
program involve application of Equations 1, and 3 through 7 in the text. The dosimetric 
calculations for determining an age-dependent, annual CEDEage group for 137Cs remain 
the same as that performed prior to 2005. However, the dosimetric calculation 
performed beginning in 2005 for determining an age-dependent, annual CEDEage group 
for 239+240Pu differs from that applied prior to 2005 (see Appendix C for calculations used 
from 1998 to 2004 to obtain an age-dependent, annual CEDEage group for 239+240Pu). The 
calculation for the age-dependent, annual CEDE for 239+240Pu was changed beginning in 
2005 because it is more in agreement with currently accepted dosimetry and biokinetic 
modeling practice used by the U.S. Department of Energy (ACJ & Associates, Inc., 
2004). As indicated in Eq. 7 in the text, the age-specific, annual TEDEage group for an 
individual during a calendar year is the sum of age-specific, annual CEDEage group for 
both 137Cs (from whole-body counting) and 239+240Pu (excreted in urine), if the activities 
of both are measured; or, can be the age-specific, annual CEDEage group for either one, if 
the activity of only one is measured. 
The first step in the process of determining a CEDEage group for 137Cs that is 
applicable to the hypothetical human volunteer is to apply Eq. B-1 (which is Eq. 1 in the 
text) with the appropriate information from Table B-1. The result of this calculation is the 
number of transformations per year (t y−1) occurring in the body of a hypothetical human 
volunteer during the year of measurement. 
Example Calculations for Deriving CEDEage group from Measurement(s) of 137Cs 
Activity by Whole-Body Counting 
Six examples (I-VI) of calculations are presented to illustrate the computation of 
an annual age-specific CEDEage group for a hypothetical volunteer. The first three 
examples (Table B-1) address the calculation of a CEDEage group from measurement(s) 
of 137Cs activity by whole-body counting. The next three examples (Table B-2) show the 
computation of an annual age-specific CEDEage group for 239+240Pu based on 
measurement(s) of 239+240Pu activity excreted in urine. The purpose of these six 
example calculations is to make transparent the method described in the text. It is 
important to note that these calculations are all examples for hypothetical human 
volunteers and so the results from the examples demonstrate methodology and do not 
apply to any specific individual currently involved in the Marshall Islands individual 
radiological surveillance monitoring program. Additionally, it is important to restate here 
the process yields conservative estimates of dose and a result ≥10 mrem-y will normally 
evoke a more accurate and complete dose calculation and/or investigation of intake. 
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Table B-1. Data for computing the CEDEage group for 137Cs applicable to a hypothetical volunteer based on measurement(s) of 
137Cs activity by whole-body counting. 
 
 
 
 
Example 
no. 
 
 
Characteristics 
of hypothetical 
human 
volunteer 
 
 
 
Total number 
of 
measurements 
performed (N)
 
 
 
 
Measurement 
number (i) 
 
 
 
Calendar date for 
measurement (i) 
during 365-d year 
Numerical 
calendar day 
representing 
time (t) of 
measurement 
(i) 
 
 
 
Recorded 
activity (kBq) for 
measurement (i)
Applicable dose 
conversion factor 
[DCF; Sv per 
transformation] (see 
Table 1 in text and 
also App. A.) 
–15I Adult male 1 1 October 1 274 0.19 1.16 × 10
        
II Adult female 2 1 November 1 304 0.07 –15
   2 December 15 348 0.03 
1.39 × 10
        B-3
III Teenager 6 1 June 1 152 0.700  
   2 August 2 214 0.781 
   3 September 3 246 0.756 
 
–15   4 October 4 277 0.742 1.41 × 10
   5 November 5 309 0.603 
   6 December 6 340 0.523 
 
 
        
Table B-2. Data for computing the CEDEage group for 239+240Pu applicable to a hypothetical volunteer based on measurement(s) of 
239+240Pu activity excreted in a 24-h urine void. 
 
 
 
Example 
no. 
 
Characteristics 
of hypothetical 
human 
volunteer 
 
 
Total number of 
measurements 
performed (N) 
 
 
 
Measurement 
number (i) 
 
 
Calendar date for 
measurement (i) 
during 365-d year 
Numerical 
calendar day 
representing 
time (t) of 
measurement (i)
 
Recorded 
activity (μBq) 
for a 24-h 
urine void (i) 
Applicable CFCEDE for 
50 y commitment [Sv 
per μBq/y]; (see 
Table 2 in text and 
also Appendix A) 
IV Adult 1 1 July 29 210 1.0 3.3 × 10–7
        
V Teenager 2 1 April 4 94 2.0 
   2 October 29 302 3.1 
5.0 × 10–7
        
VI Adolescent 6 1 February 1 32 1.2 
   2 March 29 88 1.1 
   3 June 1 152 1.5 
   4 August 15 227 0.9 
   5 September 30 273 2.1 
   6 November 14 318 1.7 
 
 
8.3 × 10–7
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 mi =i th measurement of whole-body activity (kBq) in a series from 1 up to N 
measurements taken during the calendar year (e.g., i = 1, 2, … N), and where 
N–1 is equal to zero the summation term defaults to a value of zero; 
ti =calendar day of i th measurement (e.g., 1, 2, … 150, …… up to 365 d-1; or 
366-1 in a leap year); and 
ucf =unit conversion factor of 8.64 × 107 [representing the product of 1000 t s−1 
(or Bq kBq−1) and 24 h d−1 × 3600 s h−1]. 
For Example I, where only one measurement of whole-body activity (kBq) is 
made (i.e., N – 1), Eq. B-1 will be populated with the data shown in Table B-1 
(specifically, row 1). 
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Because N – 1 for this example is equal to zero, the summation term (in Eq. B-1) 
defaults to a value of zero. Accordingly, Eq. B-1 yields the following result: 
y
t
d kBq
s Bq 
y
d kBq  
y
t  .At
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⎛ , where 1 Bq = 1 transformation 
per second (t s−1) and so the product of the numerator Bq and s is transformations. 
The number of transformations committed into the future, and which will be 
assigned to the year of measurement (t y−1), for the individual for whom the 
measurement applies are determined using Eq. B-2 (which is Eq. 3 in the text) and the 
appropriate data for this example from Table B-1 (specifically, row 1). 
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The transformations committed into the future are assigned to the year of 
measurement for the hypothetical volunteer and are combined with those 
transformations occurring during the measurement year. This is done by summing At 
and A  using Eq. B-3 (which is equal to Eq. 4 in the text): c
Csto  applicable, AAA 137ctT  +=  Eq. B-3 
      B- 5
  1−×=×+×=  yt 10  8.34  10  2.35  10  5.99 A 9 99T
The total number of transformations (t) applicable to the year of measurement 
can then be multiplied by the appropriate dose conversion factor (DCF; for example, Sv 
per transformation in the last column of first row of data in Table B-1) as shown in Eq. 
B-4 for an adult male (which is the same as Eq. 5 in the text). 
 Eq. B-4 adult maleTgroupage DCFACEDE ×= 
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The value obtained using Eq. B-4 can then be converted to mrem y−1 using the 
unit conversion factors appearing in Eq. B-5. This value can be used as an input term to 
determine the age-specific, annual TEDE (mrem y−1), which can then be compared to 
the regulatory TEDE of 15 mrem y−1 (and would be the only term, if only exposure to 
137Cs is involved). 
1-3
  ymrem 0.97   or   remSvy
  Eq. B-5 
mrem  10  rem  Sv ×××= − 26 101068.9maleadultCEDE
.1− ymrem  1 about or  
In Example II (also in Table B-1), two measurements of whole-body activity (kBq) 
are made (i.e., N = 2) for an adult-female, hypothetical human volunteer. For this 
example, Eq. B-1 will be populated with the following data shown in row 2 and 3 of data 
in Table B-1 (Example II). 
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This arithmetic produces the following result: 
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 The activity that will be produced in the future (i.e., and is responsible for 
committed dose) for the hypothetical female volunteer in this example and assigned to 
the current calendar year of measurement is determined using Eq. B-2, which yields the 
following results: 
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⎡ ×+×=  0.03cA ) , and so 
y
t 
d kBq
s Bq     dd 
y
t 87 107131064.81432880030 ×=⎟⎟⎠
⎞
⎜⎜⎝
⎛ ××⎟⎟⎠
⎞
⎜⎜⎝
⎛ +=⎟⎟⎠
⎞
⎜⎜⎝
⎛
.
y
 
y
 ..Ac  
The total number of committed transformations for the year of measurement is 
then determined using Eq. B-3. 
y
t989 104421071310072 ×=×+×=+=⎟⎟⎠
⎞
⎜⎜⎝
⎛
...AA ctA y
t
T   
Finally, the CEDE for 137Cs based on two whole-body counting measurement(s) 
applicable to an adult female is determined using Eq. B-5, where the DCF that is 
applied appears in the last column of Example II data presented in Table B-1. 
 female  adultgroup ageCEDE DCFAT ×=
  
y
Sv
t
Sv   
y
tCEDE female adult
6159 1039.31039.11044.2 −− ×=×××=
The value obtained using Eq. B-4 can then be converted to mrem y−1 using the unit 
conversion factors appearing in Eq. B-5. This value can be used as an input term to 
determine the age-specific, annual TEDE (mrem y−1), which can then be compared to 
the regulatory TEDE of 15 mrem y−1 (if only exposure to 137Cs is involved). 
1326 30101010393 −− ≈×××=  ymrem    
rem
mrem  
Sv
rem  
y
Sv   CEDE female adult .    .  
Example III shows how to compute the CEDEage group for 137Cs based on 
multiple (six) whole-body counting measurements performed for a hypothetical 
teenager during a measurement year. 
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⎥⎥
⎥⎥
⎥⎥
⎦
⎤
⎢⎢
⎢⎢
⎢⎢
⎢⎢
⎢⎢
⎢⎢
⎢⎢
⎢⎢
⎣
⎡
⎥⎦
⎤⎢⎣
⎡ −×⎟⎠
⎞⎜⎝
⎛ +
+⎥⎦
⎤⎢⎣
⎡ −×⎟⎠
⎞⎜⎝
⎛ +
+⎥⎦
⎤⎢⎣
⎡ −×⎟⎠
⎞⎜⎝
⎛ +
+⎥⎦
⎤⎢⎣
⎡ −×⎟⎠
⎞⎜⎝
⎛ +
+⎥⎦
⎤⎢⎣
⎡ −×⎟⎠
⎞⎜⎝
⎛ +
+−×+×
=⎟⎟⎠
⎞
⎜⎜⎝
⎛
d kBq
s Bq 
d d kBq kBq  
d d  kBqkBq  
d d kBq kBq  
d d kBq kBq 
d d kBq kBq  
d d kBq d kBq 
y
t 71064.8
)309340(
2
523.0603.0
)277309(
2
603.0742.0
)246277(
2
742.0756.0
)214246(
2
756.0781.0
)152214(
2
781.0700.0
340365523.0152700.0
tA , 
y
t1010182 ×= .tA   Such that for this example; 
The activity that will be produced in the future for this hypothetical volunteer, and 
assigned to the current calendar year of measurement, is determined using Eq. B-2 and 
yields the following results. 
( ) ( ) ( )36002410001102ln
9.02
2ln
1.05230 ×××⎥⎦
⎤⎢⎣
⎡ ×+×= d d  .Ac  , and 
( ) ( ) ( ) y
t 9104763600241000110
2ln
9.02
2ln
1.05230 ×=×××⎥⎦
⎤⎢⎣
⎡ ×+×= ..Ac  
The total number of committed transformations for the year of measurement is 
then determined using Eq. B-3. 
y
t
y
t 10910 108321047.61018.2 ×=×+×=+=⎟⎟⎠
⎞
⎜⎜⎝
⎛ .AAA ctT  
Finally, for this example the CEDE for 137Cs based on six whole-body counting 
measurement(s) applicable to a teenager is determined using Eq. B-5: 
 
y
SvDCFCEDE TeenagerTeenager
51510 1099.31041.11083.2 −− ×=×××=×= TA  
The value obtained using Eq. B-4 can then be converted to mrem y−1 using the 
unit conversion factors appearing in Eq. B-5. This value can be used as an input term to 
determine the age-specific, annual TEDE (mrem y−1), which can then be compared to 
the regulatory TEDE of 15 mrem y−1 (if only exposure to 137Cs is involved). 
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 1 
Teenager  ymrem 4ely approximat or ;rem
mrem    
Sv
rem   
y
Sv    CEDE −− ×××= 325 101010993. . 
 
Example Calculations for Deriving CEDEage group from Measurement(s) of 239+240Pu 
Activity Excreted in a 24-h Urine Void 
For AMS measurement(s) of 239+240Pu in one or more 24-h urine void(s) over a 
calendar year for a hypothetical adult, teenager, or adolescent volunteer enrolled in the 
Marshall Islands radiological surveillance monitoring program, the annual CEDEage group 
can be calculated using the following two-step approach. 
First, 239+240Pu activity (μBq y−1) excreted in urine for the entire calendar year of 
measurement(s) is determined for the individual. This is done using Eq. B-1 (which is 
the same as Eq. 1 in the text). 
Next, total annual activity in urine is multiplied by the applicable CFCEDE obtained 
from the last column of data in Table B-2. 
This approach is put into practice in the following three additional examples (see 
Table B-2), which pertain to 1) an adult for which a single measurement of 239+240Pu 
excreted in urine is made during a 365-d calendar year; 2) a teenager for which two 
measurements of 239+240Pu excreted in urine are made during a 365-d calendar year; 
and 3) an adolescent for which six measurements of 239+240Pu excreted in urine are 
made during a 365-d calendar year. 
For the adult for which a single measurement of 239+240Pu in urine is made (see 
Example IV in first row of data in Table B-2), the activity for the year of measurement for 
this hypothetical human volunteer is found using Eq. B-1 without the units conversion 
factor (ucf) and using as input the daily activity of 239+240Pu (μBq d−1) measured in the 
urine sample(s) (which is consistent with Eq. 1a found prior to Eq-6 in text), i.e., 
 
( ) ( ) ⎥⎦
⎤⎢⎣
⎡ =+⎥⎦
⎤⎢⎣
⎡ −×+⎥⎦
⎤⎢⎣
⎡ ×=⎟⎟⎠
⎞
⎜⎜⎝
⎛ ∑−
=
1
1
2103650.121
N
i
tA 0d d d
μBq d 10
d
μBq .0
y
μBq  
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 Again, because N – 1 in this case is equal to zero, the summation term defaults 
to a value of zero. Consequently, this equation yields the following result; 
( ) ( )[ ]
y
μBq 36502103650.12100.1 =+−×+×=tA   
The CEDEage group is determined for this example by multiplying the annual activity 
by the applicable CFCEDE (Sv per μBq y−1), which appears in last column of Example IV 
in Table B-2. This value can serve as an input term to determine the age-specific, 
annual TEDE (mrem y−1), which can then be compared to the regulatory TEDE of 15 
mrem y−1 (and would be the only term, if only exposure to 239+240Pu is involved). Using 
the equation: 
 group) CEDE(ageAdult CFCEDE ×= tA
Sv
μBq/y
 Sv 
y
μBq CEDEAdult
47 102.1103.3365 −− ×=××=  
This example yields an annual TEDE for the year of measurement of 1.2 × 10−2 rem y−1 or 
12 mrem y−1 (refer to related discussion on the use of an annualized TEDE on p. 5 and 6 
based on 100 rem per Sv). 
For the next example (see Example V in Table B-2) a teenager is considered to 
be the hypothetical human volunteer and to provide two 24-h urine voids for analysis of 
239+240Pu. The activity for the year of measurement for this hypothetical human volunteer 
is found using Eq. B-1 without using the units conversion factor (which is consistent with 
Eq. 1a in text), i.e., 
( ) ( )
( ) ⎥⎥
⎥⎥
⎦
⎤
⎢⎢
⎢⎢
⎣
⎡
⎥⎦
⎤⎢⎣
⎡ −×+
+⎥⎦
⎤⎢⎣
⎡ −×+⎥⎦
⎤⎢⎣
⎡ ×
=⎟⎟⎠
⎞
⎜⎜⎝
⎛
d d 
d
Bq
d d 
d
Bq .1d 4
d
Bq .0
y
Bq
94302
2
1.30.2
302365392
μ
μμ
At
μ  
This equation yields the following result: 
y
Bqμ .At
210149 ×=  
The CEDEage group is determined for this example by multiplying the annual activity 
excreted in the urine by the applicable CFCEDE (Sv per μBq y−1) for this example (see last 
column of data in Table B-2). This value can serve as an input term to determine the 
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 age-specific, annual TEDE (mrem y−1), which can then be compared to the regulatory 
TEDE of 15 mrem y−1. Using the equation: 
 ),( groupageCEDEt CFA ×=TeenagerCEDE
Sv 
μBq/y
Sv 
y
μBq CEDETeenager
47 106.4100.5914 −− ×=××=  
This example yields an annual TEDE for year of measurement of 4.6 × 10−2 rem y−1 (based 
on 100 rem per Sv) or 46 mrem y−1. 
For the last example (see Example VI in Table B-2) an adolescent is considered to 
be the hypothetical human volunteer and to provide six 24-h urine voids for analysis of 
239+240Pu. The activity for the year of measurement for this hypothetical human volunteer 
is found using Eq. B-1, without using the units conversion factor (which is consistent 
with Eq. 1a in text). In this example; 
( ) ( )
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⎡ −×⎟⎠
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⎞
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)227273(
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)3288(
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318365131
d d 
d
μBq
d d 
d
μBq
d d 
d
μBq
d d 
d
μBq
d d 
d
μBq.2
d d 
d
μBq .7d 2
d
μBq .2
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μBq
tA  
This equation yields the following result: 
y
μBq tA 2101.5 ×=  
The CEDEage group is determined for this last example by multiplying the annual 
activity excreted in the urine by the applicable CFCEDE (Sv per μBq y−1) for this example. 
The applicable CFCEDE can be found in the last column of Example VI data in Table B-2. 
This value can serve as an input term to determine the age-specific, annual TEDE 
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 (mrem y−1), which can then be compared to the regulatory TEDE of 15 mrem y−1. Using 
the equation: 
 group) CEDE(ageAdolescent CFCEDE ×= tA
 Sv 
μBq/y
Sv      
y
μBq  CEDEAdolescent
47 102.4103.8510 −− ×=××=
 
This example yields an annual TEDE for the year of measurement of 4.2 × 10−2 rem y−1 
(based on 100 rem per Sv) or 42 mrem y−1. 
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APPENDIX C 
 
 
 
 
 
 
Marshall Islands Dosimetry for Plutonium Isotopes in 
Urine for Calendar Years 1988 through 2004 
The measurements of 239Pu and 240Pu by AMS in a 24-h void of urine indirectly reflect 
the presence of these plutonium isotopes in the body at the time of excretion.  
Specifically, this plutonium elimination rate, which can be described in units of activity 
and expressed as micro-Becquerel (μBq) of 239+240Pu (combined) activity excreted (lost) 
per day, is referenced back to the amount of 239+240Pu activity in the body at the time of 
measurement by biokinetic relationships. This appendix provides an applied method for 
evaluating the dose from 239+240Pu based on urinary excretion measurements. This 
method of dose evaluation was applied to measurement data collected from volunteers 
from 1998 to 2004. As noted in Appendix B, this procedure was replaced beginning in 
2005 by one that is more in agreement with currently accepted dosimetry used by the 
U.S. Department of Energy (AJC & Associates, Inc., 2004). Like the method described 
in Appendix B, calculations made using this procedure were designed to yield 
conservative dose estimates and were also subject to thresholds for performing further 
investigations. 
 C-1 
 C-2 
f
Systemic organs that receive the majority of the dose from plutonium or are of 
particular dosimetric concern are bone, liver, and gonads. Under steady state 
conditions, systemic plutonium partitions ( ) are 0.5, 0.5, and 0.0035 for the bone, 
liver, and gonads, respectively. Thus for a constant steady-state activity of plutonium, 
the number of transformations during the year in the systemic organs is given by 
Eq. C-1: 
Dosimetry 
Biokinetic Relationship 
Terminology 
The method of determining the systemic content of plutonium assumes that 50% 
of the plutonium deposited in the body is eventually eliminated via the urinary excretion 
pathway. Under equilibrium conditions, the amount of plutonium eliminated via the 
urinary pathway is one-half of the steady-state levels of plutonium in the systemic 
compartment. Therefore, for every Becquerel (Bq) measured in the urine, there are two 
Becquerel of plutonium in the systemic compartment. To maintain a steady state of 2 Bq 
in the systemic compartment, an input of 2 Bq must also occur. The input assumes 
deposition into the lung via the inhalation pathway. Most compartments within the lung 
have a rapid turnover and provide a minor contribution to the dose. However, the lung 
compartments that supply the bulk of the plutonium to the systemic compartment are 
longer-term compartments that will, under steady state conditions, maintain a 2 Bq 
inventory and will contribute the greatest amount of dose to the lung. These steady 
state relationships are illustrated in Fig. C-1.  
The organs of the body that do not have a direct external input source (i.e., food, 
water, air) are “systemic” organs. Collectively these organs are the systemic 
compartment. Within the “systemic” compartment are specific organ or tissue 
compartments each of which contains a fraction of any activity deposited in the systemic 
compartment. 
d
s
y
d 41064.8365 ××××= organsystemicorgan fAT
organT
systemicA
 
 = total systemic activity associated with 239+240Pu (Bq). 
 = number of transformations that occur in the organ during the year of 
measurement, and 
 , where Eq. C-1 
  
365 
720
720
Systemic
Lung
Urine 
50%
365 
50%
Figure C-1. Equilibrium Assumptions for Plutonium Dosimetry using only Urinary Excretion Data. 
Inhalation
Example: 
If 1 Bq day−1 is excreted in the urine over the year 
(365 days), then under equilibrium conditions (i.e., 
input rate equals output rate) the systemic 
compartment would contain 720 Bq of activity that is 
divided among the major systemic organs. 
The long term retention compartments of the Lung are 
considered to be at equilibrium with the systemic 
compartment and are the primary input to the 
compartment. Therefore, the long term compartments 
of the lung contain the same activity as the systemic 
compartment. 
Feces 
 
C
-3
 Similarly, the number of transformations in the lungs can be computed using 
Eq. C-2: 
d
s 
y
d 86400365 ××= LungLung AT  Eq. C-2 
T  = Transformations (t) per year for a critical organ (e.g., lung); and  Lung
= Activity (t/s) in critical organ (e.g., lung)  ALung 
The annual dose to each organ is evaluated using the transformations derived for 
each organ (see Eq. C-3): 
kg
 J
Gy 1 SEE
y
t 
kgMeV  
g  J ××××= − organorgan TDE 10106.1 , where Eq. C-3 
 = the dose equivalent to the organ (Gy), and organDE
SEE =  specific effective energy (as obtained from and defined by the 
1
  tg
MeV )    ICRP;
ICRP weighting factors convert the dose equivalent to the effective dose 
equivalent (EDE). These weighting factors and the SEE values used for calculations 
described in this appendix are provided in Table C-1.  
The effective dose equivalent (EDE) for the organ is computed from Eq. C-4:  
 (see Table C-1, column 2 for definition of wT) Eq. C-4 Torganorgan wDEEDE ×=
Table C-1. ICRP specific effective energy (SEE) and weighting factors (wT) used for 
Marshall Islands Pu dosimetry prior to 2005. 
 
Organ 
 
ICRP Weighting Factor (w ⎟⎠
⎞⎜⎝
⎛
t  g
MeV  SEE 
T) 
Lung 0.12 0.1 
Liver 0.06 0.058 
Bone 0.03 0.21 
Gonads 0.25 3 
                                                 
1 SEE values for 239Pu and 240Pu are approximately the same value. 
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 The annual effective dose equivalent for the measured intake is equal to the sum 
of the organ effective dose equivalents: 
 Eq. C-5 GonadsBoneLiverLungAnnual EDEEDEEDEEDEEDE +++=
Under steady state conditions, the annual effective dose equivalent will be 
committed for each year. The committed effective dose equivalent (CEDE) under 
steady-state conditions over a 70-y life span of time is determined using Eq. C-6:  
CEDE70 = EDEAnnual × 70 y  Eq. C-6 
The following assumptions apply to the computation of the CEDE70: 
• Intake via inhalation, 
• Chronic exposure, 
• Continuous (steady state) intake rate, and 
• All compartments are in equilibrium 
This analysis accounts for the committed dose from the time of measurement to 
70 years in the future. Doses from samples collected in subsequent year doses are 
computed without correction for residual activity from previous doses. This mode of 
subsequent year computation is highly conservative and will tend to over-estimate 
lifetime doses. Doses prior to the first bioassay measurement are not implied or 
evaluated in this analysis. Multiple samples are rarely obtained within the same year, 
however, if multiple samples were obtained, the total transformations used in the dose 
computations are computed from time weighted systemic and lung activity values. 
Age-Dependent Dosimetry 
Internally deposited alpha particles comprise most of the dose delivered from 
plutonium. These particles have a short range and tend to deposit all of their energy into 
the organ of uptake. When computing the SEE, ICRP incorporated the weight of the 
organ as divisor. Therefore, an age adjustment can be performed by multiplying the 
SEE by a ratio of the adult to the organ mass in the age group of interest. The organ-
mass ratios used in the calculations described in this appendix appear in Table C-2. 
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 Table C-2. Lists of adult to age-group of interest organ-mass ratios used for SEE 
adjustment factors for age-dependent dose calculations. 
 
Organ 
 
Adult 
Teenager 
(15 y) 
Pre-teenager 
(10 y) 
Adolescent 
(5 y) 
Lung 1.00 1.54 2.21 3.45 
Liver 1.00 1.29 2.03 3.08 
Bone 1.00 1.00 1.76 3.24 
Gonads 1.00 2.26 18.52 21.47 
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